ensitrelvir

Indications

• investigational treatment of outpatient Covid-19
  • may reduce long Covid-19 symptoms

* reduces symptoms of mild-moderate Covid-19 by ~1 day

* reduces number of days patients test positive for Covid-19

Dosage

• 125 mg superior to 250 mg PO QD within 5 days of symptom onset

* median time to resolution of Covid-10 symptoms 24 hours sooner than placebo

* SARS-CoV2 viral titers negative within a median of 36 hours vs 65 hours with placebo

* 87% reduction of infectious SARS-Cov2 at day 4

Adverse effects

• was well tolerated, no serious treatment-related adverse events or deaths
• most common treatment-related adverse events
  • temporary decreases in HDL cholesterol increased serum triglycerides

Mechanism of action

• 3C-like protease inhibitor that targets SARS-Cov2
  • maintains activity across different variants including Omicron

More general terms

• antiviral agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=162533924
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=162623410